Azura Ophthalmics Ltd. has divulged codrugs consisting of an immunomodulator moiety and a keratolytic agent reported to be useful for the treatment of eye and dermatological disorders.
Lhotse Bio Inc. has identified lysophosphatidic acid receptor 1 (LPAR1; EDG2) antagonists reported to be useful for the treatment of cancer and fibrosis, among others.
Chiesi Farmaceutici SpA has synthesized pyrrolidine derivatives acting as discoidin domain-containing receptor DDR1 and DDR2 inhibitors reported to be useful for the treatment of fibrosis and idiopathic pulmonary fibrosis (IPF).
Researchers at Voronoi Bio Inc. and Voronoi Inc. have disclosed receptor-interacting serine/threonine-protein kinase 1 (RIPK1; RIP-1) inhibitors reported to be useful for the treatment of cancer, inflammatory bowel disease, psoriasis, rheumatoid arthritis, myocardial infarction, Alzheimer's disease, asthma and type 1 diabetes, among others.
Research at Pathios Therapeutics Ltd. has led to the identification of tricyclic psychosine receptor (GPR65) antagonists reported to be useful for the treatment of cancer, asthma, acute respiratory distress syndrome, chronic obstructive pulmonary disease and autoimmune diseases.
A recent Glaxosmithlline Intellectual Property (No 4) Ltd. and Ideaya Biosciences Inc. patent describes the development of thiadiazolyl derivatives acting as DNA polymerase θ (POLQ) inhibitors reported to be useful for the treatment of cancer.
Nicoya Therapeutics (Shanghai) Co. Ltd. has reported the identification of compounds acting as dual endothelin ETA receptor and angiotensin AT1 receptor antagonists.
RSS